Dignitana AB Publishes Q1 2024 Interim Report
Continued progress with increasing activity and awareness
Financial highlights Q1 2024
- Net Sales amounted to 21.2 MSEK (21.5), a decrease of 2 percent over the same quarter in 2023.
- Operating Result amounted to -5.0 MSEK (-3.5).
- Net Result after financial items amounted to -5.1 MSEK (-3.9).
- EBITDA for the First Quarter is negative at -1.1 MSEK (0.2).
- Earnings per share were -0.07 SEK (-0.06).
- Cash Balance amounted at 2.8 MSEK (11.7).
- Average Daily Treatment Revenue (ADTR)* was 241 TSEK (242) in the quarter.
Business highlights during the period
- Dignitana held an Extraordinary General Meeting to resolve on the rights issue and to obtain a bridge loan.
- Dignitana convened Training Academy bringing distributors to Lund Headquarters.
- DigniCap Delta received market approval in Japan with Konica Minolta as Dignitana’s Distribution partner.
- Dignitana signed OncoMedical for distribution in Switzerland and Liechtenstein.
- Preliminary result of DigniCap Delta study in Uruguay demonstrated very high efficacy compared to previous studies.
- DigniCap Delta study is underway in Brindisi, Italy.
- Dignitana nominated for Inaugural Texas Impact Enterprise Awards.
- Dignitana invited to address MedTech innovation on a panel at SXSW® conference in Texas.
Business highlights after the period
- Dignitana Rights Issue was fully subscribed at 19.1 MSEK before issue cost.
- Fredrik Jonsson appointed as CEO beginning 1 May 2024 following resignation of Caterina Lowenadler.
- Dignitana signed an exclusivity agreement with Konica Minolta as distributor for DigniCap in Japan.
- Dignitana exhibited at the Oncology Nursing Congress in Washington, DC
Key Figures
| DIGNITANA GROUP | Q1 2024 | Q1 2023 | Full year 2023 |
| Net sales, TSEK | 21,165 | 21,489 | 86,063 |
| Total revenues, TSEK | 21,288 | 21,605 | 89,025 |
| Net profit after financial items, TSEK | -5,056 | -3,938 | -17,228 |
| Cash and bank balances, TSEK | 2,839 | 11,726 | 6,027 |
| Earnings per share before and after dilution, SEK | -0.07 | -0.06 | -0.25 |
| Average Daily Treatment revenue*, TSEK | 241 | 242 | 239 |
*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-05-2024 08:00 CET.
For More Information Contact
Melissa Bourestom, Chief Communications Officer, melissa.bourestom@dignitana.com +1 469-518-5031
About Dignitana
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.
Tags: